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1. Introduction. 
A molecular understanding of the class I MHC molecule has been pivotal in deciphering its central 
role in T cell immunity. From the initial descriptions of class I MHC architecture (Bjorkman et al., 
1987), which highlighted a highly polymorphic groove containing electron density corresponding to 
bound antigen peptides, structural analyses of pMHC complexes, to date still predominantly 
focussed on X-ray crystallographic approaches, have led the way in our efforts to understand MHC 
function. While these have established fundamental molecular principles underlying peptide antigen 
presentation and T cell recognition (Madden, 1995), structural studies of pMHC molecules continue 
to provide major insights into the critical role of antigenic peptides in disease pathogenesis (Illing et 
al., 2012; Ostrov et al., 2012), immunotherapeutic strategies (Hoppes et al., 2014; Madura et al., 
2015) and into poorly understood aspects of T cell recognition, such as posttranslationally modified 
peptides (Mohammed et al., 2008, 2017; Petersen et al., 2009). 
Despite the advent of recombinant methods, availability of extended screens, introduction of 
crystallisation nanovolume robotics and dramatic technological advances in synchrotron radiation 
sources, the requirement to overcome the “crystallisation bottleneck” is still a significant 
impediment to such X-ray crystallographic analyses of pMHC (Warke and Momany, 2007). 
Consequently, reliably achieving structure determinations for predefined pMHC targets can be 
challenging, a fact exacerbated by the huge diversity of MHC alleles and antigenic peptides of 
interest. In addition to standard crystallisation techniques such as sparse matrix sampling and 
seeding techniques (Bulek et al., 2012), a number of novel strategies are available to facilitate 
crystallisation of challenging proteins, including the surface-entropy reduction approach 
(Derewenda, 2010) involving substitution of lengthy side chains with Ala, Ser, His and Tyr, and 
chemical modification of Lys residues by reductive methylation (Walter et al., 2006). These clearly 
have proven utility but are not successful for every protein, and also have the potential to interfere 
with the delicate chemistry of the biologically critical class I MHC antigen-binding groove. An 
alternative is the use of non-covalent crystallisation protein chaperones (Bukowska and Grütter, 
2013). This approach involves co-crystallising a target protein, such as an antibody fragment, and can 
promote crystallisation by reducing target conformational heterogeneity and providing an additional 
surface for crystal contacts (Griffin and Lawson, 2011). While superficially appealing, it is unclear 
how this approach could best be applied to pMHC molecules. 
Post-translationally modified peptides have emerged as an important group of antigens relevant to 
both autoimmunity and cancer. Phosphorylated peptides are increasingly recognised as promising 
tumour-associated antigens (Mohammed et al., 2017; Zarling et al., 2000; Depontieu et al., 2009; 
Cobbold et al., 2013) and recent studies have focused on establishing the molecular ground rules for 
phosphopeptide presentation by class I MHC molecules (Mohammed et al., 2008; Petersen et al., 
2009). Our own initial molecular studies in this area, which focussed on peptides bearing 
phosphorylations at P4 (so called “canonical” phosphorylations, the most prevalent in the HLA-A2-
restricted phosphopeptide repertoire), outlined clearly how the P4 phosphate moiety can mediate 
energetically significant contacts to positively charged MHC residues, while remaining highly 
prominent within the antigen-binding groove, and available for TCR recognition. Based on these 
findings the phosphate was defined as a novel “phosphate surface anchor” (Mohammed et al., 
2008). 
Subsequent to these studies, we sought to address two outstanding questions in phosphopeptide 
immunology: firstly, how conformationally distinct phosphopeptide antigens are compared to their 
non-phosphorylated counterparts (Mohammed et al., 2017) – an issue highly relevant for 
therapeutic targeting of phosphopeptide antigens, and secondly, how peptides bearing 
phosphorylations at positions other than P4 are accommodated in the MHC antigen binding groove 
– about which only very limited structural data are available. We prioritised structural studies on a 
range of specific pMHC complexes to address these questions, which focussed on both non-
phosphorylated counterparts of previously structurally analysed P4 phosphopeptides and 
phosphopeptides bearing “non-canonical” (i.e. non-P4) phosphorylations. However, difficulties in 
crystallising both of these classes of pMHC complexes led us to explore different approaches to 
circumvent this problem. 
This study describes a non-covalent crystallisation chaperone methodology to efficiently facilitate 
crystallisation of pMHC molecules, which exploits a natural ligand interaction involving LILRB1. This 
strategy has been applied to both conventional and post-translationally modified peptide-HLA-A2 
complexes that were recalcitrant to crystallisation, facilitating both crystallisation and structure 
determination. This provides a new approach to catalyse molecular studies of immunobiologically 
important pMHC complexes. Although our results focus on HLA-A2, LILRB1 is an immunoregulatory 
receptor that binds a diverse range of classical (HLA-A, HLA-B and HLA-C) and non-classical (HLA-E, 
HLA-F and HLA-G) MHC molecules (Chapman et al., 1999; Willcox et al., 2003; Dulberger et al., 2017; 
Jones et al., 2011), highlighting the potential of the method to be applied to a wider range of class I 
MHC molecules.
Table 1 Crystallisation trials for HLA-A2 molecules bound to non-canonical or non-phosphorylated peptides in the presence (dark grey)/absence (light grey) of LILRB1-Values in parentheses 
represent the number of crystallisation hits observed. Source Proteins: LSP1 - Lymphocyte Specific Protein1, POF1B - Premature Ovarian failure 1B, PKD2 - Protein Kinase D2, N4BP2 - Nedd4 
binding protein 2, AMPD2 - adenosine monophosphate deaminase 2, BCAR3 - Breast cancer anti-estrogen resistance 3, RPS17 - Ribosomal Protein S17, CHEK1 - Checkpoint kinase 1, PLEKHA6 
- Pleckstrin homology domain-containing family A member 6, HSP27 - Heat Shock Protein 27, RETREG2 - Reticulophagy regulator 2, TRAPPC1 - Trafficking protein particle complex subunit 1, 
PLEKHA6 -Phosphoinositol 3-phosphate binding protein and TAF13 - TFIID transcription initiation factor subunit 13. Commercial Screens: Molecular dimensions (Structure screen 1 + 2, Pact, 
ProPlex, BCS and JCSG+), Hampton Research (PEG/Ion, Index and PEG Rx) and Emerald Biosystems (Wizard 1–4). Generic LILRB1-pHLA-A2 crystallisation conditions: PAT (20% PEG 3350, 
Ammonium 0.2 M acetate and 0.1 M Tris-HCl pH 8.5) and PAH (20% PEG 3350, 0.2 M ammonium acetate and 0.1 M HEPES pH 7.4). 
Epitope Source protein Commercial screens (no of crystallisation hits) Total 
hits 
Collection Screening with LILRB1 (no of 
crystallisation hits) 
Total 
hits 
Collection 
RQASIELPSMAV LSP1 JSCG+ (1), Wizard 1 + 2, Pact, PEG/Ion, and Index (1) 2 No Proplex (8) and PAH (1) 9 2.7 Å 
RQASIELPSM LSP1 JCSG+ 0 n/a Not screened – – 
RTYSGPMNKV POF1B PEG/Ion, Structure Screen 1 + 2, JCSG+ and Index 0 n/a PAT (1) 1 Yet to be 
optimised 
RQASLSISV PKD2 JCSG+, BCS (1) and Wizard 1 + 2 1 1.9 Å – – – 
KMDSFLDMQL N4BP2 Index, JCSG+, PEG/Ion (1), pact and wizard 1 + 2 1 No PAT/PAH (2),PEG Rx (3), JCSG+ 
(Madden, 1995), PEG/Ion (4) and 
Structure Screen 1 + 2 (1) 
12 Yet to be 
optimised 
RQISQDVKL AMPD2 PEG/Ion (3), Pact (1), Index and BCS 4 2.1 Å – – – 
IMDRpTPEKL BCAR3 JCSG+, PEG/Ion, Structure Screen 1 + 2, Index (1), Pact 
and BCS 
1 No PAT/PAH (1) 1 Yet to be 
optimised 
KLLDFGSLpSNLQV RPS17 JCSG+, PEG/Ion, Structure Screen 1 + 2 (1), Index and 
Pact 
1 No PAT 0 
 
KLIDIVpSSQKV CHEK1 PEG/Ion, Pact, JCSG+, Index and BCS 0 n/a PAT (1) 1 Yet to be 
optimised 
SMpTRSPPRV SRp46 splicing factor BCS 0 n/a Not screened – – 
SLQPRSHpSV PLEKHA6 BCS 0 n/a Not screened – – 
RQLSSGVSEI HSP27 Pact (1), Index (2) and PEG/Ion (5) 8 No Not screened – – 
RLSSPLHFV RETREG2 PEG/Ion, Index, Pact, Structure Screen 1 + 2 and BCS 0 n/a PAT/PAH (1) and PEG/Ion (20) 21 3.2 Å 
RLQSTSERL Mitochondrial escape 
1-like 1 
Wizard 1–4 (1), JCSG+, Pact and BCS 1 No PEG/Ion 13 2.8 Å 
RTLSHISEA FLJ13725 JCSG+, Structure Screen 1 + 2, Index, ProPlex (1), 
Wizard 1–4 (1), PEG/Ion and BCS 
2 No Not screened – – 
RTFSPTYGL β-synemin/Desmulin PACT, JCSG+, Structure Screen 1 + 2, Index, Wizard 1–4, 
PEG Rx, PEG/Ion and BCS 
0 n/a PAT/PAH (1), PEG Rx (2), JCSG+ (2) 
and PEG/Ion (5) 
10 2.3 Å 
RLDSYVRSL TRAPPC1 Index, JCSG+, PEG/Ion, Pact, PEG Rx, Wizard 1 + 2 and 
BCS 
0 n/a Not screened – – 
RLFSKELRC TAF13 PEG/Ion, Wizard 1 + 2 and Pact 0 n/a Not screened – – 
 
2. Materials and methods. 
2.1 Cloning, expression and purification 
The recombinant clones of the LILRB1 D1D2 region (residues 24–221 of the mature protein; 
hereafter referred to as LILRB1) and HLA-A2 were prepared as previously reported (expression 
constructs will be made available upon request) (Willcox et al., 2003). High levels of pHLA-A2 
complexes (comprising residues 25–300 of the mature A2 heavy chain, non-covalently associated 
with β2M and peptide) and LILRB1 were produced using conventional methods involving expression 
in Escherichia coli and in vitro dilution refolding (Garboczi et al., 1992). Renatured LILRB1 and pHLA-
A2 complexes were concentrated independently, and purified by size-exclusion chromatography 
using a Superdex 200 column. 
2.2 Crystallisation, data collection and processing 
HLA-A2 molecules in complex with non-P4 phosphorylated and non-phosphorylated epitopes were 
screened against commercially available crystallisation conditions with the Mosquito nanolitre robot 
(TTP Labtech) using the vapour diffusion method (Table 1). Alternative crystallisation strategies 
involving LILRB1 were performed using a 1:1 stoichiometric mixture of purified LILRB1 and pHLA-A2 
at 10–14 mg/ ml. Diffraction-grade crystals of the LILRB1-pHLA-A2 complexes appeared after 1–2 
weeks at 23 °C (Table 1). 
Prior to X-ray data collection LILRB1-pHLA-A2 complex crystals were soaked in reservoir solution 
incorporating increasing concentrations of ethylene glycol (18–22%) and flash cooled in liquid 
nitrogen. Xray diffraction data for the LILRB1-HLA-A2ILKEPVHGV complex were collected to 2.4 Å 
resolution with the ADSC Quantum 4 detector at beamline ID14–4 (ESRF). The LILRB1-HLA-A2ILKEPVHGV 
complex crystallised in the trigonal space group P3221, with two molecules per asymmetric unit, and 
unit cell parameters a = b = 116.2 Å and c = 192.8 Å. For all other LILRB1-pHLA2-A2 complexes, X-ray 
data were collected with an ‘in-house’ MicroMax 007HF rotating anode Rigaku X-ray generator using 
a Saturn 944 CCD detector. The LILRB1- pHLA-A2 complex typically crystallizes in the trigonal space 
group P3221, with 2 molecules per asymmetric unit. All data were processed using the XDS suite 
(Kabsch, 2010) and the relevant statistics are listed in Table 2. 
2.3 Structure determination and refinement 
The 2.4 Å resolution LILRB1-HLA-A2ILKEPVHGV complex structure was solved by molecular replacement 
using MOLREP (Vagin and Teplyakov, 2010). The search model consisted of the LILRB1-HLAA2ILKEPVHGV 
complex refined to 3.4 Å resolution ((Willcox et al., 2003); PDB code 1P7Q). The LILRB1-HLA-
A2RQASIELPSMAV LILRB1-HLAA2RTFSPTYGL and LILRB1-HLA-A2RLSSPLHFV complex structures were also 
determined by molecular replacement using the high-resolution LILRB1-HLA-A2ILKEPVHGV structure 
complex as the search model with the co-ordinates of the ILK peptide moiety omitted. The 
structures were refined by alternating cycles of energy-minimization and B-factor refinement using 
CNS and REFMAC5 (Brunger et al., 1998; Murshudov et al., 2011). Manual rebuilding was performed 
with the graphics program COOT (Emsley et al., 2010). All of the complexes demonstrated 
unequivocal Fo-Fc difference density for the epitopes, which were directly built into each of the 
structures. The stereochemical and refinement parameters are listed in Table 2. Structure validation 
and analysis were carried out with CCP4 suite (Winn et al., 2011). The atomic coordinates and 
structure factors have been deposited in the RCSB Protein Data Bank. Figures were generated using 
the programs POVSCRIPT (Fenn et al., 2003), Pov-Ray (http://www.povray.org) and PyMOL 
(Schrodinger, 2015).  
 Table 2 Data processing and refinement statistics for the LILRB1-HLA-A2ILKEPVHGV, LILRB1-HLA-A2RTFSPTYGL and LILRB1-HLA-
A2RLSSPLHYV complex structures. Figures in parentheses in the data processing section apply to data in the highest resolution 
shell. 
  
LILRB1-
HLAA2-ILK 
LILRB1-HLAA2-RTFS LILRB1-HLA-A2- 
RLSS 
PDB ID code 6EWA 6EWO 6EWC 
Peptide sequence ILKEPVHGV RTFSPTYGL RLSSPLHYV 
Data processing     
   Resolution (Å) 48.6–2.4 (2.5–
2.4) 
20–2.3 (2.4–2.3) 20–3.2 (3.1–3.2) 
   Unit cell dimensions (Å) 116.1, 116.1, 
192.8 
116.3, 116.3, 192.6 117.5, 117.5, 
203.7 
   Space Group P3221 P3221 P3221 
   Total reflections 578,024 
(80872) 
758,810 (41698) 149,740 (12971) 
   Unique reflections 60,013 (8505) 66,969 (7259) 26,415 (2338) 
   Multiplicity 9.6 (9.5) 11.3 (5.5) 5.7 (5.5) 
   Completeness (%)a 99.6 (99.7) 99.1 (94) 96 (98.6) 
   Rmerge (%)b 12.2 (53.7) 10 (73.4) 17.3 (44.2) 
   I/σ(I) 
 
5.2 (1.4) 23.6 (2.8) 10.7 (3.9) 
Refinement 
   
   Resolution (Å) 48.6–2.4 19.7–2.3 19.58–3.2 
   Reflections used 56,939 63,567 26,414 
   Rcryst (%)c 22.8 23.4 20.6 
   Rfree (%)d 27.9 27.6 24.5 
   Protein residues 1101 1117 1122 
   Water molecules 45 228 – 
Model geometry 
   
   Ramachandran plot 
   
      Most favoured 90.8 89 88.5 
      Additionally allowed 8.1 9.6 10.1 
      Generously allowed 0.7 1.0 0.9 
      Disallowed 0.4 0.4 0.5 
   RMS deviations 
   
      Bond lengths (Å) 0.008 0.008 0.008 
      Bond angles (°) 1.26 1.29 1.19 
 
3. Results. 
3.1 HIL-A1 bound phosphopeptides can be refractory to crystallisation 
During our previous studies of phosphopeptide presentation by HLA-A2 we found that, whereas 
canonical P4-phosphorylated phosphopeptides were amenable to crystallisation, the majority of 
their unmodified counterparts, with the exception of a few isolated examples (Mohammed et al., 
2017, Petersen et al., 2009), proved highly intransigent to crystallisation. Similarly, structural 
determination of pMHC in complex with “non-canonical” (i.e. non-P4 phosphorylated) 
phosphopeptides was also hampered by the majority of such complexes being refractory to 
crystallisation (Table 1). Hence our attempts at structure determinations of both non-
phosphorylated pMHC and noncanonical phosphopeptide antigens highlighted the need for an 
alternative strategy to aid pMHC crystallisation. 
3.2. Validating the LILRB1 strategy for crystallising intransigent HLA-A2 molecules 
We explored the possibility of co-crystallising intransigent pMHC complexes with a natural immune 
receptor ligand. One candidate receptor that reproducibly co-crystallizes with HLA-A2 is LILRB1, 
which binds to the non-polymorphic regions of the MHC protein comprised of the α3 and β2M 
domains. Crucially, the LILRB1-pMHC interface is located distally to the peptide-binding site (Willcox 
et al., 2003), suggesting that it is highly unlikely to interfere with epitope conformation. Comparison 
of the LILRB1-HLA-A2ILKEPVHGV complex (Willcox et al., 2003) with previous structural analyses of HLA-
A2ILKEPVHGV (Madden et al., 1993) failed to note any differences in the HLA-A2 bound peptide in the 
presence/absence of LILRB1 (Willcox et al., 2003). However, LILRB1-HLA-A2ILKEPVHGV structural data 
were only available to 3.4 Å, limiting detailed analysis of the peptide conformation. To definitively 
resolve whether the binding of LILRB1 to HLA-A2 affected peptide conformation, we determined a 
higher resolution structure of the LILRB1-HLA-A2ILKEPVHGV complex (to 2.4 Å resolution (Fig. 1a)), 
which enabled a more accurate structure of the ILK peptide moiety (Fig. 1b). Structural overlay 
comparisons of this higher resolution LILRB1-HLAA2 structure with the HLA-A2ILKEPVHGV determined in 
the absence of LILRB1 (Madden et al., 1993) demonstrated that the peptide binding platform in both 
complexes was very similar with an r.m.s.d value of 0.6 Å (Fig. 1c). Most crucially, no significant 
changes in structure of the ILK peptide epitope were evident upon LILRB1 binding to HLA-A2 as 
demonstrated by the low r.m.s.d value of 0.24 Å (Fig. 1d). This confirmed that co-crystallisation of 
LILRB1 with HLA-A2 complex does not alter the conformation of the MHC-bound antigenic peptide, 
and established a basis for exploring its potential as a chaperone for facilitating crystallisation of 
pMHC complex molecules. 
3.3. LILRB1 facilitates crystallisation and structure determination of tumour-associated 
pHLA-A2-complexes 
To assess whether LILRB1 could promote the crystallisation of pMHC complexes, we selected several 
pHLA-A2 complexes that had previously proven to be refractory to crystallisation, based on 
extensive nanolitre-scale crystallisation trials using commercial screening kits, at concentrations 
commonly used for class I MHC crystallisation (typically 10–25 mg/ml). These were generally tumour 
associated phosphopeptides, and their unphosphorylated counterparts (Zarling et al., 2006). LILRB1 
and pHLA-A2 complexes were produced as previously described (Willcox et al., 2003). 
Initial attempts at crystallising pMHC complexes previously found to be refractory to crystallisation 
alone, frequently resulted in multiple hits in co-crystallisation trials with LILRB1 (Table 1). Initial 
attempts focussed on non-phosphorylated antigens, which involved equilibrating against conditions 
that had yielded LILRB1-HLA-A2ILKEPVHGV crystals, revealed a crystallisation solution (PEG 3350, 
Ammonium acetate and, Tris-HCl – hereafter referred to as PAT) that proved somewhat generic, as it 
was successful in providing useful primary hits for a diverse subset of pMHC complexes previously 
intransigent to crystallisation. An example included the 10-mer HLA-A2KMDSFLDMQL peptide complex, 
crystals of which grew with a morphology similar to that of LILRB1- HLA2ILKEPVHGV crystals (Fig. 2a), in 
the presence of LILRB1. In addition, the 12-mer HLA-A2RQASIELPSMAV complex also previously 
intransigent to crystallisation, yielded crystals with LILRB1 that grew in an optimised form of the 
generic PAT crystallisation reagent (comprised of 20% PEG 3350, 0.2 M ammonium acetate and 0.1 
M HEPES pH 7.4 – hereafter referred to as PAH) (Fig. 2b). Crucially, this same PAH condition failed to 
crystallise HLA-A2RQASIELPSMAV in the absence of LILRB1, underlining the critical chaperone function of 
LILRB1 in the crystallisation process. Importantly, the PAT condition also demonstrated considerable 
promise for crystallising HLA-A2 molecules bound to non-canonical phosphopeptides, including the 
9-mer (IMDRpTPEKL) (Fig. 2c) and 11-mer (KLIDIVpSSQKV) (Fig. 2d). 
Despite successful use of the PAT condition as a generic crystallisation condition for a subset of 
peptide-HLA-A2 complexes, for other peptide-HLA-A2 complexes fresh crystallisation hits were 
identified in the presence of LILRB1 following rescreening of complexes against commercial sparse 
matrix kits. An example was HLA-A2RTFSPTYGL, which yielded co-crystals with LILRB1 from the PEG Ion 
screen in the presence of 0.2 M potassium sodium tartrate and 20% PEG 3350 (Fig. 2e). A similar 
LILRB1 co-crystallisation screening strategy for the HLA-A2RLSSPLHFV complex resulted in initial micro-
crystals obtained in drops equilibrated against 3% Tacsimate pH 6 and 12.8% PEG 3350, after which 
further optimisations in the presence of dimethyl sulphoxide produced large well ordered LILRB1-
HLA-A2RLSSPLHFV complex crystals (Fig. 2f). Finally, it was possible to crystallise the HLA-A2RLQSTSERL 
complex, which we found previously was intransigent to crystallisation attempts, in complex with 
LILRB1 in the presence of 0.2 M Potassium Acetate and 20% PEG 3350, resulting in microcrystals 
worthy of further optimisation (Fig. 2g). 
When combining the two groups of antigens we focussed on (nonphosphorylated counterparts of P4 
phosphopeptides, and non-canonical phosphopeptides), only 10 out of the 19 pMHC complexes 
yielded hits with conventional trials (Table 1). In contrast, a majority of pMHC complexes (8/9) 
generated hits when co-crystallised with LILRB1 (Table 1). Furthermore, several complexes yielded 
multiple independent hits thereby increasing the likelihood of growing diffraction-grade crystals (> 5, 
Table 1). 
Crystals produced using the LILRB1 co-crystallisation strategy were of sufficient quality for data 
collection. Optimised LILRB1 co-crystals of the unmodified 12-mer, LILRB1-HLA-A2RQASIELPSMAV complex 
(Fig. 2d), permitted data collection and structure determination to 2.7 Å (Mohammed et al., 2017). 
Moreover, LILRB1 co-crystals of the HLAA2RTFSPTYGL and HLA-A2RLSSPLHFV complexes diffracted X-rays to 
2.3 Å and 3.2 Å, resulting in full structure determinations (Fig. 3). The quality of the resulting 
electron density maps were significantly improved using two-fold non-crystallographic symmetry 
averaging, which is present in all LILRB1-pHLA-A2 complex crystals, thereby aiding model building 
and structure determination (Fig. 3, Table 2). Collectively, these results clearly highlight the potential 
of exploiting LILRB1 as a crystallisation chaperone, to facilitate X-ray crystallographic analyses of 
biologically important peptide-HLA-A2 complexes. 
 Figure 1 Co-crystallisation of LILRB1 with HLA-A2 does not alter the conformation of the MHC-bound antigenic peptide. (a) 
Ribbon representation of the LILRB1-HLA-A2ILKEPVHGV complex structure determined to 2.4 Å resolution (HLA-A2 α chain 
(red), β2-microglobulin (yellow) and LILRB1 (cyan). (b) 2Fo-Fc electron density map contoured at 1.0 σ (blue wire) for the 
ILK peptide moiety bound within the HLA-A2 peptide binding cleft. (c) Superimposition of the HLA-A2 C-α chains 
determined in the presence (red) and absence of LILRB1 (blue). The co-ordinates for the HLA-A2ILKEPVHGV complex were 
retrieved from the PDB (accession code (1HHJ)) (Madden et al., 1993). (d) Overlay of the ILK peptide moiety derived from 
HLA-A2 in the presence (red) and absence (blue) of LILRB1. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.) 
3.4. LILRB1/HLA-A2 crystal contacts are conserved for other pMHC molecules 
To assess the possibility that this approach might also be relevant for improving crystallisation of 
other MHC molecules known to bind LILRB1 (Chapman et al., 1999), we first aligned the sequences 
of HLAA2, HLA-B27, HLA-Cw06, HLA-E, HLA-F and HLA-G1 using PRALINE (Fig. 4a). Analysis of HLA-A2 
heavy chain crystal contacts in our LILRB1-HLA-A2 complex structures highlighted that of the total 84 
residues forming crystal contacts (Fig. 4b), 44 are conserved across class I MHC, 33 are semi-
conserved and 5 are non-conserved (Fig. 4a). This demonstrates that the majority of HLA-A2 residues 
involved in forming crystal contacts within LILRB1/HLA-A2 crystals are conserved in many different 
class I MHC molecules. 
4. Discussion. 
Structural studies of class I peptide MHC structures continue to make major contributions to our 
understanding of important areas of immunobiology. However, despite availability of numerous 
pMHC structures, reliable structural analyses of predefined pMHC targets can still be challenging, as 
certain pMHC complexes can be intractable to crystallisation. This represents a significant 
impediment to molecular studies aiming to define the role of MHC-restricted antigenic peptide 
epitopes in specific immunobiological contexts such as disease pathogenesis and 
immunotherapeutic development. In the context of MHC alleles that have been crystallised, this 
phenomenon is superficially surprising, given conservation of the alpha chain and β2M, and the fact 
that only the peptide moiety would be altered between each individual pMHC complex. Whilst the 
molecular basis underlying it is unclear, it is likely to result from the hugely diverse properties of 
bound peptides. Given the strong link between protein stability and propensity for crystallisation, 
one significant factor is likely to be the wide span of peptide binding affinities for MHC, and the 
relative kinetics of complex dissociation and aggregation, versus crystal nucleation. However, our 
demonstration that peptides with similar epitope sequence and binding affinities, such as RQA_V in 
its phosphorylated and non-phosphorylated states (Mohammed et al., 2017), may not exhibit the 
same propensity for crystallisation, suggests that factors other than peptide affinity, such as the 
potential of peptide conformation to favour or disrupt crystal packing interactions, or differential 
complex solubility, are likely to be relevant to crystal formation. 
In this study we investigated a novel strategy for circumnavigating crystallisation of intransigent 
pMHC complexes. The approach relies upon the addition of a natural ligand of class I MHC, LILRB1, 
to promote alternative, and in many cases more optimal crystal packing contacts. Our findings, 
focused in this study on the HLA-A2 allele, highlight that LILRB1 can serve as an effective non-
covalent crystallisation chaperone for peptide-HLA-A2 complexes. This strategy offers several 
advantages. Firstly, since co-crystallisation with LILRB1 does not perturb the biologically critical α1α2 
peptide-binding platform, it allows bone fide peptide conformation to be observed. Secondly, the 
approach is experimentally highly feasible. LILRB1 is easily over-expressed in large amounts into E. 
coli inclusion bodies (typical yields of 100 g/l), and renaturation and purification is relatively 
efficient. Moreover, peptide-HLA-A2 crystallisation optimisation with LILRB1, which exploits a 
generic crystallisation condition in many cases, is extremely efficient, and results in the production 
of large crystals within a relatively short time interval (< 2 weeks), often of a sufficient size for data 
collection. Although we did not formally prove that all such crystals were of LILRB1-HLA-A2 complex, 
single protein controls (HLAA2 or LILRB1 alone) did not yield crystals under similar conditions. 
Furthermore, both the timescale of crystallisation, the crystal morphology and when x-ray data were 
collected the trigonal space group and unit cell constants were all characteristic of LILRB1-HLA-A2 
complex crystals. Moreover, while such crystals yield acceptable data using ‘in-house’ sources, 
clearly use of synchrotron sources would inevitably improve resolution further. In addition, the 
availability of the higher resolution structure of LILRB1 provides useful model-based phase 
information necessary for resolving LILRB1-pHLA-A2 complexes, a process that has become 
increasingly routine since all LILRB1-pHLA-A2 crystals exhibit similar unit cell constants, even if 
grown in chemically distinct conditions. Typically, the presence of two LILRB1-HLA-A2-petide 
complexes in the asymmetric unit allows non-crystallographic symmetry averaging, improving the 
quality of the electron density. Thirdly, based on the evidence we present here, LILRB1 co-
crystallisation is clearly an approach capable of catalyzing crystallisation of a diverse range of 
peptides in the context of HLA-A2, including those previously intransigent to crystallisation. 
 Figure 2 Crystallisation of intransigent HLA-A2-peptide complexes with LILRB1. Crystal morphologies of LILRB1-HLA-
A2KMDSFLDMQL (a), LILRB1-HLA-A2RQASIELPSMAV (b), LILRB1-HLA-A2IMDRpTPEKL (c), LILRB1-HLA-A2KLIDIVpSSQKV (d), LILRB1-HLA-
A2RTFSPTYGL (e), LILRB1-HLA-A2RLSSPLHFV (f) and LILRB1-HLA-A2RLQSTSERL (g). 
Two observations highlight that the LILRB1 chaperone approach we outline here might be applicable 
to different class I MHC molecules. Firstly, LILRB1 is known to recognize a broad range of class I 
pMHC molecules, which is explained by its recognition of a relatively nonpolymorphic region of the 
class I MHC molecule (the α3 domain, as well as β2-microglobulin) that is substantially conserved 
across different of different classical (HLA-A, -B, -C) and non-classical (HLA-E, -F, −G) molecules. 
Secondly, a majority of HLA-A2 residues involved in forming crystal contacts within LILRB1-HLA-A2 
crystals are conserved in a diverse range of classical/non-classical class I MHC molecules. Therefore 
there is considerable potential for extending the current strategy to facilitate crystallisation of a 
more diverse range of class I MHC molecules, although this is a focus for future studies. 
Development of LILRB1 as a crystallisation chaperone for pMHC could have several applications. 
Immune presentation and recognition of post-translationally modified peptide antigens is 
increasingly recognised as an area of immunobiological importance, not least in the context of 
cancer immunosurveillance and immunotherapy. We have successfully applied the method to 
dissect the effects of phosphorylation on peptide conformation. Of relevance in this context, so-
called “non-canonical” phosphopeptide HLA-A2 complexes, for which limited structural data are 
available, have proven to be relatively intransigent to conventional crystallisation attempts; 
furthermore unmodified counterparts of naturally occurring phosphopeptides tend to be notably 
lower affinity, and would be expected to represent challenging crystallisation targets. Use of LILRB1 
as a crystallisation chaperone facilitated crystallisation of several such peptides. In addition, the 
method may also be particularly suitable for longer, more bulged peptides (either unmodified or 
those bearing bulky post-translational modifications), where conventional class I MHC crystal 
packing interactions may be disrupted. Of relevance to this grouping, exhaustive conventional 
attempts to crystallise the bulky 12-mer unmodified HLAA2RQASIELPSMAV complex x failed entirely, 
despite in this case an equivalent affinity to the naturally phosphorylated form. The LILRB1 
chaperone approach quickly led to its structure determination, allowing us to demonstrate that 
phosphorylation of this leukaemia-associated epitope resulted in an unprecedented conformational 
change relative to this unmodified form, creating a highly distinct conformational “neoepitope” 
(Mohammed et al., 2017). Indeed, examination of the structure of unphosphorylated HLA-
A2RQASIELPSMAV in complex with LILRB1 provided a molecular explanation for its failure to crystallise 
alone, highlighting a more pronounced bulge to the peptide conformation at P8 (Proline) that 
precluded crystallisation in the same mode as the phosphorylated form (HLA-A2RQApSIELPSMAV) by 
causing steric clashes with a neighbouring molecule. This observation highlights that altered crystal 
contacts introduced by LILRB1 co-crystallisation can clearly circumvent such problems. A second 
scenario, peptide anchor modification, which is an immunotherapeutic approach used to boost 
antigen immunogenicity whereby peptide immunogens are engineered with modified anchor 
residues to optimise MHC binding, is another setting where the LILRB1 crystallisation chaperone 
methodology could be productively applied. Here the intention is to increase MHC affinity but 
without altering peptide conformation presented to TCR. Structural comparisons of unmodified and 
modified forms (the former by definition of low affinity) are likely to be highly informative in this 
setting. In addition, there has been considerable interest in the potential to crystallise ‘empty’ class I 
MHC molecules that lack bound peptide, and this would be another worthy application of the LILRB1 
crystallisation chaperone approach. 
 Figure 3 Crystal structures of LILRB1-HLA-A2RTFSPTYGL and LILRB1-HLA-A2RLSSPLHFV complexes. (a) Ribbon representation of the 
LILRB1-HLA-A2RTFSPTYGL complex structure determined to 2.3 Å resolution (HLAA2 α chain (green), β2-microglobulin (yellow) 
and LILRB1 (cyan). (b) 2Fo-Fc electron density map contoured at 1.0 σ (blue wire) for the RTF peptide moiety bound within 
the HLA-A2 peptide binding groove. (c) Ribbon representation of the LILRB1- HLA-A2RLSSPLHFV complex structure determined 
to 3.2 Å resolution (HLA-A2 α chain (purple), β2-microglobulin (yellow) and LILRB1 (cyan). (d) 2Fo-Fc electron density map 
contoured at 1.0 σ (blue wire) for the RLS peptide moiety bound within the HLA-A2 peptide binding cleft. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
In light of our results, we propose that other class I MHC receptors could be exploited as alternative 
crystallisation chaperones - for class I pMHC, the two most likely candidates are LILRB2 and CD8αα, 
both of which bind to a broad range of class I MHC molecules (Chapman et al., 1999; Gao et al., 
2000). Moreover, previous structural studies of both LILRB2 and CD8αα immune receptors in 
complex with class I MHC have highlighted that they interact with sites of the MHC that are distal to 
the antigen binding platform and therefore are highly unlikely to influence epitope conformation 
(Gao et al., 1997; Shiroishi et al., 2006). LILRB2 displays an overlapping but distinct MHC-I 
recognition mode relative to LILRB1 and predominantly mediates hydrophobic contacts to the HLA-G 
α3 domain (Shiroishi et al., 2006). Moreover, structural comparisons of HLA-G and its bound peptide 
in the presence and absence (Clements et al., 2005) of LILRB2 have demonstrated no substantial 
shifts in conformation (Fig. 5a–b) thus confirming the potential of LILRB2 as a tool for promoting 
protein crystallisation of nonclassical MHC molecules. In contrast, the CD8αα-MHC binding 
interaction mode significantly differs to that of LILRB1 and LILRB2 forming interactions with the α2 
and α3 domains of HLA-A2 as well as β2M (Gao et al., 1997), but similarly has no significant effects 
on the conformation of the α1α2 peptide binding platform (Fig. 5c–d). Therefore LILRB2 and CD8αα 
could have potential as crystallisation chaperones for pMHC. Importantly, the fact that LILRB1/B2 
receptors are human/ primate receptors and absent in rodents precludes use of them as 
crystallisation chaperones for mouse pMHC crystallisation. However, CD8αα, and also the murine 
LILR orthologue paired immunoglobulin-like receptor-B (PIR-B), both recognize a broad range of 
murine class I MHC molecules, and represent candidates for an analogous non-covalent 
crystallisation chaperone approach. In summary, the success we have observed with the LILRB1 co-
crystallisation approach suggests that this method offers an effective means for promoting 
crystallisation of intransigent HLA-A2 complexes. We predict that co-crystallisation of pMHC 
molecules with LILRB1 will be a valuable addition to the growing repertoire of tools available to 
resolve the macromolecular crystallisation bottleneck for class I pMHC molecules.  
 
Figure 4 Conservation of HLA-A2 alpha chain crystal contacts within HLA-A2-LILRB1 complex structures. a) Sequence 
alignment of select class I MHC molecules that bind LILRB1. Sequences were obtained from Uniprot (accession numbers 
P01892 (HLA-A2:01), P13747 (HLA-E), P03989 (HLA-B27:02), P17693 (HLA-G1), P30511 (HLA-F) and Q29963 (HLA-Cw06:02)) 
and aligned with Praline. The colour scheme of the alignment is for amino acid conservation. HLA-A2 alpha chain residues 
that contribute to crystal contacts in the HLA-A2-LILRB1 complex structures are highlighted (pink star). b) Ribbon 
representation of HLA-A2 heavy chain derived from HLA-A2-LILRB1 complex structure (green). For clarity the LILRB1 and 
β2M molecules have been omitted. HLA-A2 alpha chain residues that contribute to crystal contacts have been mapped 
(pink spheres). (For interpretation of the references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
 
 
 
Figure 5 Co-crystallisation of LILRB2 or CD8αα with MHC class I molecules does not affect the conformation of the bound 
antigenic peptide. (a) Superimposition of the HLA-G C-α chains determined in the presence (purple) and absence (pink) of 
LILRB2. The co-ordinates were retrieved from the PDB (accession codes for HLA-GRIIPRHLQL (1YDP) (Clements et al., 2005) and 
HLA-GRIIPRHLQLLILRB2 (2DYP) (Shiroishi et al., 2006) (b) Overlay of the RII peptide moiety derived from HLA-G in the presence 
(purple) and absence (pink) of LILRB2. (c) Superimposition of the HLA-A2 C-α chains determined in the presence (yellow) 
and absence (blue) of CD8αα. The co-ordinates were retrieved from the PDB (accession codes for HLA-A2ILKEPVHGV 
(1HHJ)(Madden et al., 1993) and HLAA2ILKEPVHGV-CD8αα (1AKJ) (Gao et al., 1997)(d) Overlay of the ILK peptide moiety 
derived from HLA-A2 in the presence (yellow) and absence (blue) of CD8αα. (For interpretation of the references to colour 
in this figure legend, the reader is referred to the web version of this article.)  
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